title: Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.
abstract: The nucleoside analogues acyclovir (ACV) and famciclovir (FCV) reduce the frequency and severity of herpes simplex virus 2 (HSV-2) genital shedding, yet despite their high potency in vitro and a lack of induced drug resistance, frequent episodes of breakthrough mucosal shedding occur. We tested a published stochastic, spatial mathematical model of HSV-2 replication and spread, in concert with pharmacokinetic and pharmacodynamic equations, against virologic data from clinical trials of twice-daily acyclovir and famciclovir suppression. The model reproduced the key features of clinical trial data, including genital shedding episode rate, expansion and decay dynamics, and heterogeneous peak viral production and duration. In simulations, these agents shortened episode duration by limiting the extent of viral production by 1 to 2 log units and limiting the formation of secondary ulcers by ∼50%. However, drug concentrations were noninhibitory during 42% of the dosing cycle. Even if drug concentrations were high at episode initiation, prolonged episodes often ensued due to drug decay over ensuing hours and subsequent rebound of rapidly replicating HSV-2. The local CD8(+) T-cell density was more predictive of episode viral production (R(2) = 0.42) and duration (R(2) = 0.21) than the drug concentration at episode onset (R(2) = 0.14 and 0.05, respectively), though the model projected that an agent with an equivalent potency but a two times longer half-life would decrease shedding by 80% compared to that of standard twice-daily regimens. Therefore, long half-life is a key characteristic of any agent that might fully suppress HSV-2 reactivations.
authors.affiliation: Department of Medicine, University of Washington, Seattle, Washington, USA.
authors.forename: Joshua T
authors.initials: JT
authors.lastname: Schiffer
authors.forename: David A
authors.initials: DA
authors.lastname: Swan
authors.forename: Lawrence
authors.initials: L
authors.lastname: Corey
authors.forename: Anna
authors.initials: A
authors.lastname: Wald
mesh_terms: D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D000212:Acyclovir / Q000493:pharmacokinetics* / Q000494:pharmacology; D000998:Antiviral Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D001682:Biological Availability; D018414:CD8-Positive T-Lymphocytes / Q000821:virology; D002986:Clinical Trials as Topic; D003198:Computer Simulation; D004334:Drug Administration Schedule; D000077595:Famciclovir; D006207:Half-Life; D006558:Herpes Genitalis / Q000188:drug therapy / Q000821:virology; D018258:Herpesvirus 2, Human / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D018655:Lymphocyte Count; D015233:Models, Statistical; D019562:Viral Load / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects; D017201:Virus Shedding / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D015075:2-Aminopurine; D000077595:Famciclovir; D000212:Acyclovir
references.citation: Trends Pharmacol Sci. 2009 Dec;30(12):610-6
references.pmid: 19837466
references.citation: Nature. 1995 Jan 12;373(6510):123-6
references.pmid: 7816094
references.citation: Lancet. 2012 Feb 18;379(9816):641-7
references.pmid: 22225814
references.citation: J Infect Dis. 2011 Aug 15;204(4):554-61
references.pmid: 21791657
references.citation: JAMA. 1990 Mar 23-30;263(12):1662-4
references.pmid: 2308204
references.citation: Sci Transl Med. 2011 Jul 13;3(91):91ra63
references.pmid: 21753122
references.citation: Front Immunol. 2013 Jul 29;4:209
references.pmid: 23908652
references.citation: J Infect Dis. 2008 Oct 15;198(8):1141-9
references.pmid: 18783315
references.citation: Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18973-8
references.pmid: 20956313
references.citation: J Clin Invest. 1997 Mar 1;99(5):1092-7
references.pmid: 9062368
references.citation: Sex Transm Dis. 2006 Sep;33(9):529-33
references.pmid: 16540883
references.citation: Sci Transl Med. 2009 Nov 18;1(7):7ra16
references.pmid: 20161655
references.citation: Nat Immunol. 2009 May;10(5):524-30
references.pmid: 19305395
references.citation: J Infect Dis. 2010 Feb 15;201(4):499-504
references.pmid: 20088691
references.citation: Nature. 2012 Nov 15;491(7424):463-7
references.pmid: 23075848
references.citation: J Infect Dis. 2003 Nov 1;188(9):1345-51
references.pmid: 14593592
references.citation: J Exp Med. 2007 Mar 19;204(3):595-603
references.pmid: 17325200
references.citation: Biol Blood Marrow Transplant. 2011 Feb;17(2):259-64
references.pmid: 20615475
references.citation: J Antimicrob Chemother. 2011 Nov;66(11):2593-600
references.pmid: 21865349
references.citation: Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716-20
references.pmid: 202961
references.citation: Nature. 1978 Apr 13;272(5654):583-5
references.pmid: 205792
references.citation: Nat Med. 2009 Aug;15(8):886-92
references.pmid: 19648930
references.citation: J Virol. 2003 Apr;77(8):5037-8
references.pmid: 12663814
references.citation: Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10289-94
references.pmid: 9294203
references.citation: Elife. 2013 Apr 16;2:e00288
references.pmid: 23606943
references.citation: J Infect Dis. 2004 Aug 15;190(4):693-6
references.pmid: 15272395
references.citation: Antimicrob Agents Chemother. 2002 Mar;46(3):762-8
references.pmid: 11850259
references.citation: J Infect Dis. 2005 Sep 15;192(6):1102-7
references.pmid: 16107966
references.citation: Lancet. 2000 May 27;355(9218):1845-50
references.pmid: 10866439
references.citation: Vaccine. 2008 Jul 29;26(32):4034-40
references.pmid: 18565628